Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8551880 | 0.86 | AR (0.53) | ARALDH1A1POLBGAAFNTA | |
| SCHEMBL14656413 | 0.85 | SLC22A12 (0.48) | ARALDH1A1L3MBTL1POLBGAA | |
| SCHEMBL28676047 | 0.84 | AR (0.46) | ARALDH1A1POLBGAASLC22A12 | |
| SCHEMBL3164186 | 0.81 | GAA (0.63) | ARALDH1A1POLBGAAKMT2A | |
| SCHEMBL22169511 | 0.80 | AR (0.54) | ARALDH1A1POLBGAASLC22A12 | |
| SCHEMBL6742359 | 0.80 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1POLBKMT2AKDM4E | |
| SCHEMBL4809997 | 0.79 | SLC22A12 (0.47) | ARALDH1A1L3MBTL1POLBSLC22A12 | |
| SCHEMBL2810532 | 0.77 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1POLBGAAKMT2A | |
| SCHEMBL14661877 | 0.77 | EPAS1 (0.50) | SLC22A12FFAR4 | |
| SCHEMBL25285812 | 0.76 | CYP19A1 (0.50) | ARALDH1A1CYP19A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1699783-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-1699783-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-07-25 | — | — | EP | disclosed |
| US-7414132-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414132-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414132-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-20070112036-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070112036-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070112036-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-05-17 | — | — | US | disclosed |
| EP-1699783-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005066164-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112036-A1 | Opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | AR 229/4885ALDH1A1 2092/4885L3MBTL1 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.